https://www.selleckchem.com/pr....oducts/azd5153-6-hyd
T-ALL expansion in immunocompromised mice was significantly impaired using this drug combination, relative to mice receiving control vehicle or single drug treatment, highlighting the immediate clinical relevance of this drug combination for high risk T-ALL patients. Our results thus provide a strategy to improve the efficacy of current chemotherapy platforms and circumvent GC resistance. Copyright © 2020, Ferrata Storti Foundation.The study aim was to compare the ratio of T1WI to T2WI signal intensity (T1/T2)
Like
Comment
Share
